{"disease":{"id":"neovascular-age-related-macular-degeneration-namd","name":"neovascular age related macular degeneration namd"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07308639","title":"DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06929143","title":"A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06075147","title":"The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2500,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT07516132","title":"Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":850,"lead_sponsor_name":"Ocular Therapeutix, Inc.","has_results":false},{"nct_id":"NCT06890026","title":"Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration","phase":"","overall_status":"COMPLETED","enrollment_count":742,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT04543331","title":"Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema","phase":"","overall_status":"COMPLETED","enrollment_count":572,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04657289","title":"A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":451,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT07482176","title":"Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":284,"lead_sponsor_name":"Adverum Biotechnologies, Inc.","has_results":false},{"nct_id":"NCT06856577","title":"Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":284,"lead_sponsor_name":"Adverum Biotechnologies, Inc.","has_results":false},{"nct_id":"NCT06795048","title":"A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":274,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT06116890","title":"Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":180,"lead_sponsor_name":"Kyowa Kirin Co., Ltd.","has_results":false},{"nct_id":"NCT05269966","title":"Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":105,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06817915","title":"This Project At LMU Looks At How Using AI 2nd Opinion Report to Analyze Retinal Eye Scans Impact Doctors' Decisions About Treatment for Patients with a Specific Eye Disease (nAMD)","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Johannes Schiefelbein","has_results":false},{"nct_id":"NCT04764656","title":"Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for nAMD in Portugal","phase":"","overall_status":"TERMINATED","enrollment_count":81,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05562947","title":"A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":68,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT07406438","title":"To Evaluate the Safety, Pharmacokinetics, and Efficacy of GB10 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Shenzhen Kexing Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT05282004","title":"Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Sandoz","has_results":true},{"nct_id":"NCT05989126","title":"Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT07088445","title":"Therapeutic Prospects of Faricimab Injection for Patients Affected by Neovascular Age-Related Macular Degeneration","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":35,"lead_sponsor_name":"Hui Peng","has_results":false},{"nct_id":"NCT05161806","title":"Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Sandoz","has_results":true},{"nct_id":"NCT05904691","title":"Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":19,"lead_sponsor_name":"Ocugenix Corporation","has_results":false},{"nct_id":"NCT06623279","title":"Open-laBel Dose-escalation Study for CRISPR/cas13- Rna TargetInG THerapy for the Treatment of Neovascular Age-related Macular Degeneration in Phase I Trial","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":15,"lead_sponsor_name":"HuidaGene Therapeutics Co., Ltd.","has_results":false},{"nct_id":"NCT06031727","title":"CRISPR/cas13-medIated RNA TarGeting THerapy for the Treatment of Neovascular Age-related Macular Degeneration Investigator-initiated Trial (SIGHT-I)","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":12,"lead_sponsor_name":"HuidaGene Therapeutics Co., Ltd.","has_results":false},{"nct_id":"NCT05903794","title":"A Study of EXG102-031 in Patients With wAMD (Everest)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Exegenesis Bio","has_results":false},{"nct_id":"NCT04746963","title":"Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"AsclepiX Therapeutics, Inc.","has_results":true},{"nct_id":"NCT06398080","title":"An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting","phase":"","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false}],"total":26},"guidelines":[],"source":"Drug Landscape verified database"}